Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Nov 17:11:764758.
doi: 10.3389/fonc.2021.764758. eCollection 2021.

Highlighting the Place of Metastasis-Directed Therapy in Isolated Liver Metastases in Prostate Cancer: A Case Report

Anne-Emmanuella Yeo  1 , Aurore Hendrix  1 , Caterina Confente  1 , Nicolas Christian  2 , Baudouin Mansvelt  3 , Géraldine Pairet  4 , Emmanuel Seront  1
Affiliations
Case Reports

Highlighting the Place of Metastasis-Directed Therapy in Isolated Liver Metastases in Prostate Cancer: A Case Report

Anne-Emmanuella Yeo et al. Front Oncol. .

Abstract

Metastatic prostate cancer remains a challenge for clinicians. Metastases involve mainly the bone compartment and can manifest as oligometastatic disease. In this setting, the role of metastasis-directed therapies (MDT) including surgery and/or stereotactic body radiotherapy is currently evaluated. Visceral metastases are less common and have very poor prognosis in mPC. Whether treating isolated visceral metastases such as liver metastases with MDT could increase the prognosis remains unknown. We report the management of a prostate cancer patient who progressed on androgen deprivation therapy with apparition of two liver metastases. We describe the feasibility of combining MDT with abiraterone acetate and prednisone in a patient with metastatic castration-resistant prostate cancer. MDT allowed the interruption of abiraterone acetate, preventing cumulative toxicity of this agent.

Keywords: abiraterone acetate; case report; liver metastasis; metastasis-directed therapy; oligometastatic; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Timeline.
Figure 2
Figure 2
MRI liver revealed two metastases: (A) in segment VII and (B) straddling segments V and VI.
Figure 3
Figure 3
Histopathology findings of liver biopsy lesions confirming prostatic origin with cribriform pattern (A). Positive staining for PSA (B). Hematoxylin and eosin stain (×20) (C).
Figure 4
Figure 4
Dose distribution of the stereotactic body of radiotherapy (50 Gy in five fractions) of lesion (B) (coils) post radiofrequency of lesion (A).
See this image and copyright information in PMC

References

    1. Rawla P. Epidemiology of Prostate Cancer. World J Oncol (2019) 10(2):63–89. doi: 10.14740/wjon1191 - DOI - PMC - PubMed
    1. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, et al. . Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol (2016) 34(14):1652–9. doi: 10.1200/JCO.2015.65.7270 - DOI - PMC - PubMed
    1. Jenjitranant P, Touijer KA. Role of Surgery in Oligometastatic Prostate Cancer. Prostate Int (2019) 7(4):125–30. doi: 10.1016/j.prnil.2019.10.001 - DOI - PMC - PubMed
    1. Van Poppel H, De Meerleer G, Joniau S. Oligometastatic Prostate Cancer: Metastases Directed Therapy? Arab J Urol (2016) 14(3):179–82. doi: 10.1016/j.aju.2016.06.004 - DOI - PMC - PubMed
    1. Rao A, Vapiwala N, Schaeffer EM, Ryan CJ. Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure? Am Soc Clin Oncol Educ Book (2019) 39:309–20. doi: 10.1200/EDBK_239041 - DOI - PubMed

Publication types

LinkOut - more resources